Abstract:Background The level of expression of a mutation-associated neoantigen (MANA) is a critical determinant of effective T cell priming.1 Thus, interventions that increase the expression of a protein containing a MANA could increase responses to immune checkpoint inhibitors (ICI), especially for tumors with relatively low mutation burden like microsatellite stable (MSS) colorectal cancer (CRC).1 We have shown that radiation therapy (RT) upregulates the expression of genes containing MANA in a preclinical model, resulting in enhanced presentation of the derived MANA.2 We also found expansion of CD8 T cells against a MANA upregulated in expression by RT in a lung cancer patient with complete response to RT+ipilimumab.3 Here we set out to test if MANA upregulation is a common response of human tumors to RT. Methods Patient-derived tumor organoids (PDO) from colorectal (CRC) (n=3) (figure 1a) and lung (n=4) cancer were characterized for radiation response4 (figure 1b). PDOs were then irradiated with doses of 5-8 Gy daily for 3 days (RT) or left untreated (UT) and RNAseq performed 24h post-RT. Differentially expressed genes were identified using DESeq2 differential expression analysis. Ingenuity Pathway Analysis (IPA) was used to identify pathways modulated by RT. Results In the CRC PDO, 2034 and 362 genes were found to be concordantly upregulated and downregulated, respectively, by RT (figure 1c). Upregulated genes were associated with p38 MAPK signaling and innate immune signaling pathways (figure 1d). This RT-modulated gene set was used to interrogate predicted MANA dataset from CRC patients [1]. We found that ≥1 MANA-encoding gene was predicted to be significantly upregulated by RT in 263/266 patients from the TCGA COADREAD MSS cohort (figure 2a). The median number/patient of upregulated MANA was 11 (range 0-79), while for downregulated MANA it was 0 (range 0-15, figure 2b). In the lung PDO, 439 and 117 genes were found to be concordantly upregulated and downregulated, respectively, by RT. Upregulated genes were largely associated with DNA damage response pathways. We found that ≥1 MANA-encoding gene was predicted to be significantly upregulated by RT in 29/35 patients from a lung cancer dataset.5 The median number/patient of upregulated MANA was 3 (range 0-25), while for downregulated MANA it was 0 (range 0-14). Conclusions Our data support the novel concept that RT can uncloak neoantigens in tumors like MSS CRC where low neoantigen expression may preclude effective T cell priming and contribute to ICI resistance. Acknowledgements The authors are grateful for the financial support of The NIH (R01CA198533, SD) and from the AACR (21-40-12-VANN, SV). References Westcott PMK, Sacks NJ, Schenkel JM, et al. Low neoantigen expression and poor T-cell priming underlie early immune escape in colorectal cancer. Nat Cancer. 2021;2:1071–1085. Lhuillier C, Rudqvist NP, Yamazaki T, et al. Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. J Clin Invest. 2021;131(5):E138740. Formenti SC, Rudqvist NP, Golden E et al. Radiotherapy induces responses of lung cancer to CTLA-4 blockade. Nat Med. 2018;24(12):1845–1851. Martin ML, Adileh M, Hsu KS et al. Organoids reveal that inherent radiosensitivity of small and large intestinal stem cells determines organ sensitivity. Cancer Res. 2020;80(5):1219–1227. Rizvi NA, Hellmann MD, Snyder A et al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015;348(6230):124–8.

Inhibition of DNMTs increases neoantigen-reactive T-cell toxicity against microsatellite-stable colorectal cancer in combination with radiotherapy

Immunotherapy Combined with Local Therapy in the Late-Line Treatment of Repair-Proficient (pmmr)/microsatellite Stable (MSS) Metastatic Colorectal Cancer

Intratumoral Injection of Interferon Gamma Promotes the Efficacy of Anti-Pd1 Treatment in Colorectal Cancer

The Roles of Tumor-associated Neutrophils in Colorectal Cancer Treated with Different Combinatorial Immunotherapies

Radiotherapy-exposed CD8<SUP>+</SUP> and CD4<SUP>+</SUP> neoantigens enhance tumor control

Neoantigen-augmented iPSC cancer vaccine combined with radiotherapy promotes antitumor immunity in poorly immunogenic cancers

Synergistic effect of radiotherapy and dendritic-cell-based immunotherapy via miR-15b-5p regulation in a colon carcinoma mouse model

Neutrophil Extracellular Traps Blockade in Combination with PD-1 Inhibition in Treatment of Colorectal Cancer Metastasis.

ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer

A Novel Engineered AAV-based Neoantigen Vaccine in Combination with Radiotherapy Eradicates Tumors

Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy

1117 A Patient-Derived Tumor Organoid Platform to Investigate Radiation-Induced Neoantigen Exposure

Gene augmented nuclear-targeting sonodynamic therapy via Nrf2 pathway-based redox balance adjustment boosts peptide-based anti-PD-L1 therapy on colorectal cancer

Harnessing radiotherapy-induced NK-cell activity by combining DNA damage-response inhibition and immune checkpoint blockade

Dual inhibitors of DNMT and HDAC remodels the immune microenvironment of colorectal cancer and enhances the efficacy of anti-PD-L1 therapy

Harnessing NK cell-based immunotherapy to prevent the high-dose radiotherapy-inducing tumor survival recurrence

Anti-TNFR2 Enhanced the Antitumor Activity of a New HMGN1/3M-052 Stimulated Dendritic Cell Vaccine in a Mouse Model of Colon Cancer

Low-dose Immunogenic Chemotherapeutics Promotes Immune Checkpoint Blockade in Microsatellite Stability Colon Cancer

Synergistic Therapeutic Effects of Low Dose Decitabine and NY-ESO-1 Specific TCR-T Cells for the Colorectal Cancer With Microsatellite Stability

DNA-PK inhibition enhances neoantigen diversity and increases T cell responses to immunoresistant tumors

Colorectal cancer-specific IFNβ delivery overcomes dysfunctional dsRNA-mediated type I interferon signaling to increase the abscopal effect of radiotherapy